Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

pharmareview.files.wordpress.com
from pharmareview.files.wordpress.com More from this publisher
02.06.2013 Views

CITALOPRAM Synonym: nitalapram Trade name: Celexa (Forest) Indications: Depression, obsessive-compulsive disorder, panic disorder Category: Antidepressant; Selective serotonin reuptake inhibitor Half-life: 33 hours Clinically important, potentially hazardous interactions with: isocarboxazid, MAO inhibitors, phenelzine, selegiline, St John’s wort, sumatriptan, tramadol, tranylcypromine, trazodone Reactions Skin Acute febrile neutrophilic dermatosis (Sweet’s syndrome) (2004): Mecca P+, JCutanPathol31(2), 189 (with perphenazine and amoxapine) (photodistributed) Cellulitis Dermatitis Diaphoresis (11%) (2005): Tseng WP+, KaohsiungJMedSci21(7), 326 (2001): Bostic JQ+, J Child Adole Pyschopharmacol 11(2), 159 (33%) (1999): Feighner JP+, J Clin Psychiatry 60(12), 824 Eczema Exanthems (2001): Richard MA+, Ann Dermatol Venereol 128(6), 759 Facial edema Photosensitivity Pigmentation (2001): Inaloz HS+, JDermatol28(12), 742 Pruritus (

132 CLADRIBINE Vasculitis (2002): Tousi B+, Clin Lab Haematol 24(4), 259 (1 case) Other Death (2004): Ogura M+, Int J Hematol 80(3), 267 (2 cases) Gynecomastia (2001): Abhyankar D+, Leuk Lymphoma 42(1), 243 Infections (2003): Byrd JC+, Leukemia 17(2), 323 (43%) Injection-site edema (9%) Injection-site erythema (9%) Injection-site pain (9%) Injection-site phlebitis (2%) Injection-site thrombosis (2%) Myalgia/Myositis/Myopathy/Myotoxicity (7%) CLARITHROMYCIN Trade names: Biaxin (Abbott); Biaxin HP; Clacine; Clarith; Klacid; Klaricid; Macladin; Veclam Indications: Various infections caused by susceptible organisms Category: Antibiotic, macrolide Half-life: 5–7 hours Clinically important, potentially hazardous interactions with: alprazolam, aprepitant, atorvastatin, benzodiazepines, carbamazepine, chlordiazepoxide, cilostazol, clonazepam, clorazepate, colchicine, conivaptan, cyclosporine, dasatinib, diazepam, digoxin, dihydroergotamine, disopyramide, ergot alkaloids, fluoxetine, flurazepam, fluvastatin, HMG-CoA reductase inhibitors, imatinib, lapatinib, lorazepam, lovastatin, methylprednisolone, methysergide, midazolam, oxazepam, paroxetine, pimozide, pravastatin, prednisone, quazepam, repaglinide, rimonabant, sertraline, simvastatin, solifenacin, temazepam, temsirolimus, triazolam, warfarin, zidovudine Reactions Skin Baboon syndrome (2003): Wolf R+, Dermatol Online J 9(3), 2 (with amoxicillin and omeprazole) Exanthems Fixed eruption (2001): Hamamoto Y+, Clin Exp Dermatol 26(1), 48 (1988): Rosina P+, Contact Dermatitis 38, 105 Henoch-Schonlein purpura (2003): Borras-Blasco J+, Int J Clin Pharmacol Ther 41(5), 213 Phototoxicity (2002): Parkash P+, J Assoc Physicians India 50, 1192 Pruritus (1991): Poirier R, J Antimicrob Chemother 27 (Suppl A), 109 Psoriasis (1994): Ellerin P, The Schoch Letter 44, 47 (#185) (observation) Purpura (2006): Zink A+, Dtsch Med Wochenschr 131(40), 2217 (2003): Borras-Blasco J+, Int J Clin Pharmacol Ther 41(5), 213 (2002): Alexopoulou A+, Eur J Haematol 69(3), 191 Pustules Rash (sic) (3%) Stevens–Johnson syndrome (

132 CLADRIBINE<br />

Vasculitis<br />

(2002): Tousi B+, Clin Lab Haematol 24(4), 259 (1 case)<br />

Other<br />

Death<br />

(2004): Ogura M+, Int J Hematol 80(3), 267 (2 cases)<br />

Gynecomastia<br />

(2001): Abhyankar D+, Leuk Lymphoma 42(1), 243<br />

Infections<br />

(2003): Byrd JC+, Leukemia 17(2), 323 (43%)<br />

Injection-site edema (9%)<br />

Injection-site erythema (9%)<br />

Injection-site pain (9%)<br />

Injection-site phlebitis (2%)<br />

Injection-site thrombosis (2%)<br />

Myalgia/Myositis/Myopathy/Myotoxicity (7%)<br />

CLARITHROMYCIN<br />

Trade names: Biaxin (Abbott); Biaxin HP; Clacine; Clarith;<br />

Klacid; Klaricid; Macladin; Veclam<br />

Indications: Various infections caused by susceptible organisms<br />

Category: Antibiotic, macrolide<br />

Half-life: 5–7 hours<br />

Clinically important, potentially hazardous interactions<br />

with: alprazolam, aprepitant, atorvastatin, benzodiazepines,<br />

carbamazepine, chlordiazepoxide, cilostazol, clonazepam,<br />

clorazepate, colchicine, conivaptan, cyclosporine, dasatinib,<br />

diazepam, digoxin, dihydroergotamine, disopyramide, ergot<br />

alkaloids, fluoxetine, flurazepam, fluvastatin, HMG-CoA reductase<br />

inhibitors, imatinib, lapatinib, lorazepam, lovastatin,<br />

methylprednisolone, methysergide, midazolam, oxazepam,<br />

paroxetine, pimozide, pravastatin, prednisone, quazepam,<br />

repaglinide, rimonabant, sertraline, simvastatin, solifenacin,<br />

temazepam, temsirolimus, triazolam, warfarin, zidovudine<br />

Reactions<br />

Skin<br />

Baboon syndrome<br />

(2003): Wolf R+, Dermatol Online J 9(3), 2 (with amoxicillin <strong>and</strong><br />

omeprazole)<br />

Exanthems<br />

Fixed eruption<br />

(2001): Hamamoto Y+, Clin Exp Dermatol 26(1), 48<br />

(1988): Rosina P+, Contact Dermatitis 38, 105<br />

Henoch-Schonlein purpura<br />

(2003): Borras-Blasco J+, Int J Clin Pharmacol Ther 41(5), 213<br />

Phototoxicity<br />

(2002): Parkash P+, J Assoc Physicians India 50, 1192<br />

Pruritus<br />

(1991): Poirier R, J Antimicrob Chemother 27 (Suppl A), 109<br />

Psoriasis<br />

(1994): Ellerin P, The Schoch Letter 44, 47 (#185) (observation)<br />

Purpura<br />

(2006): Zink A+, Dtsch Med Wochenschr 131(40), 2217<br />

(2003): Borras-Blasco J+, Int J Clin Pharmacol Ther 41(5), 213<br />

(2002): Alexopoulou A+, Eur J Haematol 69(3), 191<br />

Pustules<br />

Rash (sic) (3%)<br />

Stevens–Johnson syndrome (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!